Mestinon 60 (Pyridostigmine Bromide)

• Mestinon 60 is an acetylcholinesterase inhibitor indicated for conditions that involve impaired neuromuscular transmission.
• Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction.
• Postoperative ileus: accelerates return of bowel function by enhancing gastrointestinal motility.

• Pyridostigmine bromide reversibly inhibits acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in synaptic clefts. By blocking this enzyme, the drug raises the concentration of acetylcholine at cholinergic synapses, especially at the neuromuscular junction, thereby enhancing transmission of nerve impulses to skeletal muscles and promoting smooth‑muscle activity in the gastrointestinal tract.

Mestinon 60 may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea or vomiting
• Diarrhea or abdominal cramps
• Increased salivation or sweating
• Muscle cramps or fasciculations
• Dizziness or headache
• Blurred vision

Serious or Rare Side Effects

• Cholinergic crisis (muscle weakness, respiratory failure)
• Severe bradycardia or heart block
• Bronchospasm or severe asthma exacerbation
• Seizures or convulsions
• Anaphylactic reaction or severe skin rash
• Hepatic dysfunction or jaundice

• Before initiating therapy, clinicians should evaluate individual risk factors and monitor for adverse events.
• Renal impairment: adjust dose based on renal function.
• Asthma or bronchospastic disease: use with caution; monitor respiratory status.
• Cardiac disease: observe for bradyarrhythmias.
• Concurrent anticholinergic drugs: may reduce efficacy; assess need for adjustment.
• Pregnancy and lactation: safety not established; discuss risks with provider.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Pyridostigmine bromide can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Anticholinergic agents (e.g., atropine, scopolamine): may markedly diminish therapeutic effect.
• Beta‑blockers (e.g., propranolol): can exacerbate bradycardia.
• Muscle relaxants used during anesthesia: may potentiate neuromuscular blockade.

Moderate Interactions (Monitor Closely)

• Aminoglycoside antibiotics (e.g., gentamicin): may increase risk of neuromuscular weakness.
• Inhaled anticholinergics for COPD (e.g., ipratropium): may reduce drug efficacy.
• Drugs affecting renal excretion (e.g., diuretics): monitor renal function and adjust dose if needed.